Embla Medical posted its financial results for the first quarter (1Q). Highlights included:
▪ Sales amounted to $232 million with 15 percent reported growth and organic growth was 4 percent, which is on par with 1Q 2025.
▪ Prosthetics and neuro orthotics sales grew by 9 percent organic, bracing and supports sales grew by 1 percent organic, while patient care was down 1 percent.
▪ Gross profit margin was 62 percent, compared to 63 percent in 1Q 2025.
▪ Earnings before interest, taxes, depreciation and amortization (EBITDA) was $40 million, and EBITDA margin was 17 percent of sales, compared to 18 percent in 2025.
▪ Net profit was $15 million and increased by 21 percent compared to the same period in 2025, with a net profit margin of 6 percent.
▪ Free cash flow totaled 4 million or 2 percent of sales, compared to 4 percent of sales in 2025.
▪ Net-bearing interest debt/EBITDA before special items was 2.4x at the end of the quarter, which is within the company’s target range of 2-3x EBITDA.
“We are seeing more favorable trends in the US patient care business and remain well on track with our strategic initiatives to support growth in the coming quarters across our global patient care business. EBITDA margin was 17 percent, reflecting the impact of external factors such as [foreign exchange] and tariffs. We continue to execute with discipline and remain focused on delivering margin expansion as growth accelerates. We reiterate our full-year guidance of 5-8 percent organic sales growth and an EBITDA margin of 20-22 percent,” said Sveinn Sölvason, president and CEO.
